PME11 Antibody

Definition and Biological Role of PME-1

PME-1 (Protein Phosphatase Methylesterase 1) is a demethylase enzyme that regulates the activity of protein phosphatase 2A (PP2A), a critical enzyme involved in cellular signaling pathways. PME-1 removes methyl groups from the carboxyl terminus of the PP2A catalytic subunit, modulating its interaction with regulatory B subunits and thereby influencing processes such as cell cycle progression, apoptosis, and stress responses .

PME-1 Antibody Characteristics

PME-1 antibodies are tools for detecting and studying the expression, localization, and function of the PME-1 protein. Two commercially available antibodies are prominently documented:

Key Features:

• ab154569: Targets a recombinant fragment (amino acids 1–300) of human PPME1 .

• 8A6-F8: Recognizes endogenous PME-1 across multiple species and is validated for Western blotting .

Research Applications

PME-1 antibodies have been utilized in diverse studies:

• PP2A Regulation: PME-1 demethylates PP2A subunits, affecting phosphatase activity in cardiac tissue and cancer models .

• Cancer Research: Overexpression of PME-1 correlates with poor prognosis in glioblastoma and prostate cancer due to PP2A inactivation .

• Neurological Disorders: PME-1 modulates tau phosphorylation in Alzheimer’s disease models .

Experimental Validation

• Western Blot: Both antibodies detect PME-1 at ~42 kDa in human, mouse, and rat lysates .

• Immunohistochemistry: ab154569 has been used to localize PME-1 in formalin-fixed paraffin-embedded tissues .

Technical Considerations

• Species Cross-Reactivity: Confirmed in human, mouse, and rat .

• Storage: Recommendations include short-term storage at 4°C and long-term storage at -20°C in glycerol-based buffers .

Limitations and Future Directions

• Specificity: While these antibodies show high specificity, off-target binding remains a concern in untested applications.

• Therapeutic Potential: Inhibiting PME-1 to reactivate PP2A is under investigation for cancer therapy .